MedTrace Logo

A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.

NCT00220818 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2010-07-22

No results posted yet for this study

Summary

The purpose of this study is to understand how quickly lansoprazole, once daily (QD), improves feeding in premature babies or babies less than 28 days of age.

Conditions

  • Gastroesophageal Reflux Disease

Interventions

DRUG

Lansoprazole

Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.

DRUG

Lansoprazole

Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
29 Days
Max Age
364 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2005-07-31
Completion
2005-07-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00220818 on ClinicalTrials.gov